Advertisement
Canada markets close in 6 hours 13 minutes

  • S&P/TSX

    21,943.05
    +57.67 (+0.26%)
     

  • S&P 500

    5,087.23
    +38.81 (+0.77%)
     

  • DOW

    38,199.83
    +114.03 (+0.30%)
     

  • CAD/USD

    0.7319
    -0.0004 (-0.06%)
     

  • CRUDE OIL

    84.10
    +0.53 (+0.63%)
     

  • Bitcoin CAD

    87,562.23
    +876.11 (+1.01%)
     

  • CMC Crypto 200

    1,378.17
    -18.37 (-1.32%)
     

  • GOLD FUTURES

    2,353.70
    +11.20 (+0.48%)
     

  • RUSSELL 2000

    1,985.17
    +4.06 (+0.20%)
     

  • 10-Yr Bond

    4.6670
    -0.0390 (-0.83%)
     

  • NASDAQ

    15,830.15
    +218.39 (+1.40%)
     

  • VOLATILITY

    15.52
    +0.15 (+0.98%)
     

  • FTSE

    8,122.12
    +43.26 (+0.54%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6832
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

Vir Biotechnology, Inc.
Updated ·1 min read
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

A live webcast of the panel can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

CONTACT: Contacts: Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189